title: Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells.
abstract: Chemokines play the key role in initiating immune responses by regulating the attraction and homing of immune cells to the lymphoid and nonlymphoid tissues. CXCL14 is a chemokine that in tumors may act as chemoattractant for monocytes and dendritic cells (DC), which may modulate antitumor immune responses in certain cancers. In this study, we investigated the mechanisms of loss of CXCL14 in prostate cancer cells. Cell treatment with the demethylating agent 5-aza-2-deoxycytidine resulted in the recovery of CXCL14 mRNA and protein expression. Hypermethylated CpG island sequences encompassing the CXCL14 gene promoter were identified. The restoration of CXCL14 by 5-aza-2-deoxycytidine treatment had functional impact, based on the DC chemoattractant activity of conditioned medium from drug-treated cells. Conversely, CXCL14 removal from conditioned media by affinity chromatography abolished its chemotactic properties, confirming that functionally active CXCL14 was generated in prostate cancer cells by relieving its transcriptional silencing with 5-aza-2-deoxycytidine. Our findings offer the first direct evidence for epigenetic regulation of chemokine expression in tumor cells.
authors.affiliation: Seoul National University College of Medicine, Seoul, South Korea.
authors.forename: Eun Young
authors.initials: EY
authors.lastname: Song
authors.forename: Michael R
authors.initials: MR
authors.lastname: Shurin
authors.forename: Irina L
authors.initials: IL
authors.lastname: Tourkova
authors.forename: Dmitriy W
authors.initials: DW
authors.lastname: Gutkin
authors.forename: Galina V
authors.initials: GV
authors.lastname: Shurin
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D001483:Base Sequence; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology; D019743:Chemokines, CXC / Q000096:biosynthesis / Q000235:genetics*; D019175:DNA Methylation / Q000187:drug effects; D000077209:Decitabine; D015536:Down-Regulation; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D011401:Promoter Regions, Genetic; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics
chemical_list: C118056:CXCL14 protein, human; D019743:Chemokines, CXC; D012333:RNA, Messenger; D000077209:Decitabine; D001374:Azacitidine
references.citation: Mol Cancer Ther. 2001 Nov;1(1):61-7
references.pmid: 12467239
references.citation: Clin Cancer Res. 1998 Mar;4(3):585-93
references.pmid: 9533525
references.citation: Methods Mol Biol. 2003;215:437-62
references.pmid: 12512319
references.citation: Trends Genet. 2000 Apr;16(4):168-74
references.pmid: 10729832
references.citation: Exp Hematol. 2006 Aug;34(8):1101-5
references.pmid: 16863917
references.citation: Oncol Rep. 2003 Sep-Oct;10(5):1237-40
references.pmid: 12883687
references.citation: J Immunol. 2000 Sep 1;165(5):2588-95
references.pmid: 10946286
references.citation: Cancer Res. 2004 Nov 15;64(22):8262-70
references.pmid: 15548693
references.citation: Cancer Res. 2002 Jun 15;62(12):3498-502
references.pmid: 12067994
references.citation: Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):710-5
references.pmid: 10639144
references.citation: J Biol Chem. 2002 Apr 26;277(17):14877-83
references.pmid: 11836256
references.citation: Annu Rev Genomics Hum Genet. 2002;3:101-28
references.pmid: 12142355
references.citation: Prostate. 2005 Jun 15;64(1):67-74
references.pmid: 15651028
references.citation: Cancer. 2000 Dec 15;89(12):2646-54
references.pmid: 11135227
references.citation: Cytokine. 2008 Nov;44(2):248-55
references.pmid: 18809336
references.citation: Cancer Res. 2001 Dec 15;61(24):8659-63
references.pmid: 11751381
references.citation: J Pathol. 2007 May;212(1):83-90
references.pmid: 17334979
references.citation: J Immunol. 2000 Mar 15;164(6):3200-6
references.pmid: 10706711
references.citation: J Exp Med. 2001 Sep 17;194(6):855-61
references.pmid: 11561000
references.citation: Immunol Cell Biol. 2002 Oct;80(5):489-96
references.pmid: 12225386
references.citation: Cancer Res. 1995 Nov 15;55(22):5195-9
references.pmid: 7585573
references.citation: Int J Cancer. 2003 Mar 10;104(1):92-7
references.pmid: 12532424
references.citation: J Clin Invest. 2000 May;105(10):1383-93
references.pmid: 10811846
references.citation: Semin Cancer Biol. 2002 Oct;12(5):331-7
references.pmid: 12191632
references.citation: Annu Rev Immunol. 2000;18:767-811
references.pmid: 10837075
references.citation: J Mol Biol. 2006 Nov 3;363(4):813-22
references.pmid: 16987528
references.citation: Nat Immunol. 2001 Feb;2(2):123-8
references.pmid: 11175804
references.citation: Cancer Res. 2004 Feb 1;64(3):969-76
references.pmid: 14871827
references.citation: J Pathol. 2008 Nov;216(3):295-306
references.pmid: 18788075
references.citation: J Immunol. 2005 May 1;174(9):5490-8
references.pmid: 15843547
references.citation: Biochem Biophys Res Commun. 1999 Feb 24;255(3):703-6
references.pmid: 10049774
references.citation: Cancer Detect Prev. 2007;31(5):359-65
references.pmid: 18037591
references.citation: Am J Pathol. 2000 Jun;156(6):1937-50
references.pmid: 10854217
references.citation: J Natl Cancer Inst. 2003 Mar 5;95(5):399-409
references.pmid: 12618505
references.citation: Int J Cancer. 2001 Oct 15;94(2):243-51
references.pmid: 11668505
references.citation: Immunity. 2005 Sep;23(3):331-42
references.pmid: 16169505
references.citation: J Invest Dermatol. 2002 Jun;118(6):915-22
references.pmid: 12060384
references.citation: Clin Cancer Res. 2007 Feb 1;13(3):832-8
references.pmid: 17289874
references.citation: Cancer Res. 2001 Dec 15;61(24):8611-6
references.pmid: 11751372
references.citation: Cancer Res. 2001 Jan 1;61(1):249-55
references.pmid: 11196170